Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 4/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6928590 | 0.85 | DAO (0.46) | GRIN1DAO | |
| SCHEMBL7739895 | 0.84 | AKR1C3 (0.36) | GRIN1CDK5CDK5R1PDE2A | |
| SCHEMBL7740618 | 0.83 | PTGES (0.38) | GRIN1PDE2A | |
| SCHEMBL6926403 | 0.83 | DAO (0.46) | GRIN1DAO | |
| SCHEMBL7198441 | 0.81 | AR (0.36) | GRIN1 | |
| SCHEMBL7735090 | 0.79 | NTRK1 (0.36) | PDE2A | |
| SCHEMBL7198556 | 0.78 | CA12 (0.33) | GRIN1 | |
| SCHEMBL7068989 | 0.78 | AR (0.41) | — | |
| SCHEMBL7199614 | 0.78 | EGLN1 (0.30) | GRIN1 | |
| SCHEMBL7740364 | 0.77 | GRIA1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6596709-B1 | For treatment of Alzheimer's disease, schizophrenia, amyotrophic lateral sclerosis, and Huntington's chorea | LES LABORATOIRES SERVIER (FR) | 2003-07-22 | — | — | US | disclosed |
| US-6518258-B1 | 6-sulphamoyl -3-quinolyphosphonic acid compounds | LES LABORATOIRES SERVIER (FR) | 2003-02-11 | — | — | US | disclosed |
| US-6486143-B2 | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-11-26 | — | — | US | disclosed |
| US-6420386-B1 | SPINAL TRAUMATISM, EPILEPSY, CHRONIC NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE, SCHIZOPHRENIA, LATERAL AMYOTROPHIC SCLEROSIS OR HUNTINGTON'S CHOREA. | LES LABORATORIES SERVIER (FR) | 2002-07-16 | — | — | US | disclosed |
| US-20010031746-A1 | 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds | LES LABORATOIRES SERVIER (FR) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031746-A1 | 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds | CA6, P2RY6, FPR3 | GRIN1 801/4885SCN10A 1227/4885CDK5 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.